Risk of developing depression from endocrine treatment: A nationwide cohort study of women administered treatment for breast cancer in South Korea
BackgroundAlthough previous studies demonstrated no association between depression and tamoxifen in patients with breast cancer, there is still a limited amount of long-term follow-up data. This study aimed to evaluate the relationship between endocrine treatment and the risk of depression.MethodsTh...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.980197/full |
| _version_ | 1818021331725189120 |
|---|---|
| author | Jooyoung Oh Jooyoung Oh Hye Sun Lee Soyoung Jeon Dooreh Kim Jeong-Ho Seok Jeong-Ho Seok Woo-Chan Park Jae-Jin Kim Jae-Jin Kim Chang Ik Yoon |
| author_facet | Jooyoung Oh Jooyoung Oh Hye Sun Lee Soyoung Jeon Dooreh Kim Jeong-Ho Seok Jeong-Ho Seok Woo-Chan Park Jae-Jin Kim Jae-Jin Kim Chang Ik Yoon |
| author_sort | Jooyoung Oh |
| collection | DOAJ |
| description | BackgroundAlthough previous studies demonstrated no association between depression and tamoxifen in patients with breast cancer, there is still a limited amount of long-term follow-up data. This study aimed to evaluate the relationship between endocrine treatment and the risk of depression.MethodsThis nationwide population-based cohort study used data obtained over a 14-year period (January 2007 to December 2021) from the Korean National Health Insurance claims database. All female patients with breast cancer were included. We examined the incidence of depression in patients who underwent endocrine treatment, and those who did not undergo endocrine treatment constituted the control group.ResultsThe data from 11,109 patients who underwent endocrine treatment and 6,615 control patients between 2009 and 2010 were analyzed. After performing matching for comorbidities and age, both groups comprised 6,532 patients. The median follow-up were 119.71 months. Before and after matching was performed, the endocrine treatment was not a significant risk factor for developing depression (p=0.7295 and p=0.2668, respectively), nor was it a significant factor for an increased risk for suicide attempt (p=0.6381 and p=0.8366, respectively).ConclusionsUsing a real-world population-based cohort, this study demonstrated that there is no evidence that the endocrine treatment increases the risk of depression. |
| first_indexed | 2024-04-14T08:17:22Z |
| format | Article |
| id | doaj.art-6eb3d2628aa449ac86cc482c761632b8 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-14T08:17:22Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-6eb3d2628aa449ac86cc482c761632b82022-12-22T02:04:21ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-09-011210.3389/fonc.2022.980197980197Risk of developing depression from endocrine treatment: A nationwide cohort study of women administered treatment for breast cancer in South KoreaJooyoung Oh0Jooyoung Oh1Hye Sun Lee2Soyoung Jeon3Dooreh Kim4Jeong-Ho Seok5Jeong-Ho Seok6Woo-Chan Park7Jae-Jin Kim8Jae-Jin Kim9Chang Ik Yoon10Department of Psychiatry, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South KoreaInstitute of Behavioral Sciences in Medicine, Yonsei University College of Medicine, Seoul, South KoreaBiostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, South KoreaBiostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, South KoreaDivision of Breast Surgery, Department of Surgery, Seoul St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South KoreaDepartment of Psychiatry, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South KoreaInstitute of Behavioral Sciences in Medicine, Yonsei University College of Medicine, Seoul, South KoreaDivision of Breast Surgery, Department of Surgery, Seoul St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South KoreaDepartment of Psychiatry, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South KoreaInstitute of Behavioral Sciences in Medicine, Yonsei University College of Medicine, Seoul, South KoreaDivision of Breast Surgery, Department of Surgery, Seoul St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South KoreaBackgroundAlthough previous studies demonstrated no association between depression and tamoxifen in patients with breast cancer, there is still a limited amount of long-term follow-up data. This study aimed to evaluate the relationship between endocrine treatment and the risk of depression.MethodsThis nationwide population-based cohort study used data obtained over a 14-year period (January 2007 to December 2021) from the Korean National Health Insurance claims database. All female patients with breast cancer were included. We examined the incidence of depression in patients who underwent endocrine treatment, and those who did not undergo endocrine treatment constituted the control group.ResultsThe data from 11,109 patients who underwent endocrine treatment and 6,615 control patients between 2009 and 2010 were analyzed. After performing matching for comorbidities and age, both groups comprised 6,532 patients. The median follow-up were 119.71 months. Before and after matching was performed, the endocrine treatment was not a significant risk factor for developing depression (p=0.7295 and p=0.2668, respectively), nor was it a significant factor for an increased risk for suicide attempt (p=0.6381 and p=0.8366, respectively).ConclusionsUsing a real-world population-based cohort, this study demonstrated that there is no evidence that the endocrine treatment increases the risk of depression.https://www.frontiersin.org/articles/10.3389/fonc.2022.980197/fullbreast cancerendocrine treatmenttamoxifenaromatase inhibitordepression |
| spellingShingle | Jooyoung Oh Jooyoung Oh Hye Sun Lee Soyoung Jeon Dooreh Kim Jeong-Ho Seok Jeong-Ho Seok Woo-Chan Park Jae-Jin Kim Jae-Jin Kim Chang Ik Yoon Risk of developing depression from endocrine treatment: A nationwide cohort study of women administered treatment for breast cancer in South Korea Frontiers in Oncology breast cancer endocrine treatment tamoxifen aromatase inhibitor depression |
| title | Risk of developing depression from endocrine treatment: A nationwide cohort study of women administered treatment for breast cancer in South Korea |
| title_full | Risk of developing depression from endocrine treatment: A nationwide cohort study of women administered treatment for breast cancer in South Korea |
| title_fullStr | Risk of developing depression from endocrine treatment: A nationwide cohort study of women administered treatment for breast cancer in South Korea |
| title_full_unstemmed | Risk of developing depression from endocrine treatment: A nationwide cohort study of women administered treatment for breast cancer in South Korea |
| title_short | Risk of developing depression from endocrine treatment: A nationwide cohort study of women administered treatment for breast cancer in South Korea |
| title_sort | risk of developing depression from endocrine treatment a nationwide cohort study of women administered treatment for breast cancer in south korea |
| topic | breast cancer endocrine treatment tamoxifen aromatase inhibitor depression |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.980197/full |
| work_keys_str_mv | AT jooyoungoh riskofdevelopingdepressionfromendocrinetreatmentanationwidecohortstudyofwomenadministeredtreatmentforbreastcancerinsouthkorea AT jooyoungoh riskofdevelopingdepressionfromendocrinetreatmentanationwidecohortstudyofwomenadministeredtreatmentforbreastcancerinsouthkorea AT hyesunlee riskofdevelopingdepressionfromendocrinetreatmentanationwidecohortstudyofwomenadministeredtreatmentforbreastcancerinsouthkorea AT soyoungjeon riskofdevelopingdepressionfromendocrinetreatmentanationwidecohortstudyofwomenadministeredtreatmentforbreastcancerinsouthkorea AT doorehkim riskofdevelopingdepressionfromendocrinetreatmentanationwidecohortstudyofwomenadministeredtreatmentforbreastcancerinsouthkorea AT jeonghoseok riskofdevelopingdepressionfromendocrinetreatmentanationwidecohortstudyofwomenadministeredtreatmentforbreastcancerinsouthkorea AT jeonghoseok riskofdevelopingdepressionfromendocrinetreatmentanationwidecohortstudyofwomenadministeredtreatmentforbreastcancerinsouthkorea AT woochanpark riskofdevelopingdepressionfromendocrinetreatmentanationwidecohortstudyofwomenadministeredtreatmentforbreastcancerinsouthkorea AT jaejinkim riskofdevelopingdepressionfromendocrinetreatmentanationwidecohortstudyofwomenadministeredtreatmentforbreastcancerinsouthkorea AT jaejinkim riskofdevelopingdepressionfromendocrinetreatmentanationwidecohortstudyofwomenadministeredtreatmentforbreastcancerinsouthkorea AT changikyoon riskofdevelopingdepressionfromendocrinetreatmentanationwidecohortstudyofwomenadministeredtreatmentforbreastcancerinsouthkorea |